KNSA - Kiniksa Pharmaceuticals, Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.00
-0.44 (-3.05%)
As of 10:39AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close14.44
Open14.22
Bid14.06 x 2200
Ask14.14 x 1300
Day's Range14.00 - 14.32
52 Week Range13.04 - 32.88
Volume47,768
Avg. Volume97,393
Market Cap765.862M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is Kiniksa Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ?
    Insider Monkey20 days ago

    Is Kiniksa Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ?

    Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. Trends reversed 180 degrees during the first quarter amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]

  • The Kiniksa Pharmaceuticals (NASDAQ:KNSA) Share Price Is Down 23% So Some Shareholders Are Getting Worried
    Simply Wall St.last month

    The Kiniksa Pharmaceuticals (NASDAQ:KNSA) Share Price Is Down 23% So Some Shareholders Are Getting Worried

    It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...

  • Is Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ?
    Insider Monkey3 months ago

    Is Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ?

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • MoneyShow3 months ago

    Long-Term "GameChangers" in Biotech

    When I'm hunting for unicorns, I start with biotech. They won't all be winners. But in a well-constructed portfolio, enough of them will hit their commercial targets with sufficient force to make their shareholders very happy, explains Hilary Kramer, editor of GameChangers.

  • Benzinga6 months ago

    The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 28) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...

  • 5 Best-Performing IPOs of 2018
    Zacks7 months ago

    5 Best-Performing IPOs of 2018

    Strong economic fundamentals and increased foreign investment have led to such a high number of companies going public.